Strides Pharma Science Limited — Board Meeting, 29-07-2025: Outcome of Board Meeting

Strides Pharma's board has approved key updates to its internal policy for fair disclosure of Unpublished Price Sensitive Information (UPSI). This move aims to ensure timely and uniform sharing of all material company news, avoiding selective disclosure. The CFO has been designated as the Chief Investor Relations Officer (CIRO) to oversee all public communications. The revised policy also clarifies how the company will handle market rumors, manage interactions with analysts, and defines legitimate business reasons for sharing sensitive data, while also requiring a digital database for such disclosures. This enhances transparency for investors.